The European market for modern plant extracts is entering a decisive phase. Between botanical innovations, new hemp-derived ingredients, stricter customs requirements, and enhanced scientific control, Europe is seeking a balance between trade openness and consumer protection. For both buyers and professionals, understanding this framework is becoming essential to distinguish promising products from those that are truly compliant.
By 2026, the message from European institutions is clear: an innovative plant extract can no longer rely on mere marketing hype to gain sustainable market access. Safety, traceability, labeling, and regulatory status are now central. In a world where consumers demand legal, laboratory-tested products offered at a fair price, this evolution is fundamentally changing how new products are sold, purchased, and evaluated.
A more active European framework for plant extracts
The European Union has clearly strengthened its role as a filter for modern plant extracts. The novel food system remains the main gateway for innovative ingredients, with a simple rationale on paper: no marketing without prior verification when a product has no significant consumption history in the EU before 1997. In practice, this means that operators must precisely document the nature of the extract, its manufacturing method, its intended use, and its safety profile.
The 2026 updates to the EU list clearly demonstrate that the system is not static. The authorization of enriched carrot rhamnogalacturonan-I, or cRG-I, on June 11, 2026, illustrates this dynamic: botanical extracts continue to advance, but only after scientific review and formal approval. For reputable brands, this is a positive sign, as it rewards those who invest in compliance rather than improvisation.
This ongoing maintenance via EUR-Lex also confirms an important point: regulations are not outdated documents that can be consulted once and for all. They evolve in step with innovations, submitted applications, and health-related decisions. For companies in the CBD, next-generation cannabinoid, or specialized plant ingredient sectors, staying up-to-date has become as much a business skill as a regulatory one.
Security remains at the heart of the system
If Europe is tightening the screws, it's primarily in the name of safety. The Commission always reiterates three key conditions for novel foods: the product must be safe, its labeling must not mislead the consumer, and it must not present any nutritional disadvantage if it replaces an existing food. These principles may seem basic, but they have very real implications for modern plant extracts.
A concentrated extract is not simply a dried plant. As soon as the composition, the concentration of certain compounds, the bioavailability, or the method of use are significantly altered, the risk profile can change. This is precisely why EFSA continues to work on appropriate risk assessment methods, with a 2025-2027 program that promises a refinement of scientific approaches from 2026 onwards, particularly around standardized procedures and multi-level analysis models.
Scientific discussions on plant contaminants and toxicology also demonstrate that European caution is not simply a matter of excessive bureaucracy. Recent work by the EFSA (European Food Safety Authority) specifically addresses contaminants in the food chain and the risks associated with certain plant substances such as lectins. For the end consumer, this serves as a crucial reminder: “natural” does not automatically mean “risk-free,” especially when discussing highly processed or enriched modern extracts.
An extract is not always novel food
One of the most misunderstood aspects of the market concerns the very status of plant extracts. Many people assume that a plant extract is either automatically authorized or automatically classified as a novel food. In reality, the situation is much more nuanced. The status depends on the history of use in the European Union, but also on the form of the product, its concentration, and the specific context of its use in food.
The Commission illustrates this with several examples in its catalogue of status. The aqueous extract of olive fruit containing at least 10% hydroxytyrosol, updated on May 20, 2025, and the 2:1 extract of Astragalus membranaceus root, are not treated as universal cases valid for all uses. Their evaluation is carried out according to specific contexts of use, which makes all the difference for manufacturers and importers.
In practical terms, an ingredient may be accepted as a food supplement in one context, but require further authorization if it is subsequently incorporated into other product categories. This is a crucial signal for companies: an extract may be considered a simple food ingredient in one scenario and a novel food in another. For informed consumers, this underscores the importance of purchasing from companies that are fully aware of the regulatory framework under which they market their products.
Botanical health claims: the major legal hurdle
Even when a product is legally marketable, another major obstacle remains: how to talk about it. In April 2025, the Court of Justice of the European Union reiterated that the use of health claims for botanical substances in advertising is currently prohibited until the Commission has completed its review of these claims. In other words, marketing cannot fill the legal gray areas.
This position has a direct impact on communication surrounding plant extracts, supplements, and many wellness products. It is not enough for an extract to be appreciated by consumers or studied in scientific literature to freely attribute health benefits to it in a product description, advertisement, or promotional image. The line between product information and therapeutic or physiological claims remains closely monitored.
Recent case law concerning a supplement containing saffron extract and melon juice reinforces this line of reasoning. For reputable brands, this necessitates clear, factual, and cautious communication. For consumers, this is rather good news: a trustworthy website should prioritize transparency regarding origin, analysis, composition, and compliance, rather than making spectacular promises that are impossible to legally substantiate.
Online commerce, customs and enhanced controls
The rise of e-commerce has profoundly changed the flow of plant extracts in Europe. The European customs reform for 2026 reflects this reality: volumes are exploding, there are more European standards to be checked at the border, and authorities want to better screen goods entering the territory. For all innovative plant-based products, this means that logistics is becoming as strategic as formulation.
The Council also approved in November 2025 the abolition of the de minimis duty exemption, with the temporary application of a duty of €3 per item from July 1, 2026, to July 1, 2028. This measure may seem technical, but it can significantly impact the final cost of many small shipments, particularly cross-border online purchases. Operators who rely on clean and well-structured supply chains will therefore have a clear advantage.
For consumers, this development could have two simultaneous effects: on the one hand, increased controls and potentially fewer dubious products easily entering the market; on the other hand, downward pressure on the prices of certain imported goods. In this context, buying from a reputable European retailer that is fast and transparent about compliance can become far more attractive than seeking the cheapest offer without any real guarantee.
Imported plant products: very concrete monitoring
Plant extracts do not circulate freely without control once they originate from non-EU countries. The Commission specifies that plants and plant products may be subject to mandatory entry channels and uniform control frequencies. Furthermore, the rules on reducing certain phytosanitary controls were further amended by Implementing Regulation (EU) 2026/1101, demonstrating that the system is constantly evolving.
In parallel, certain foods for human or animal consumption of non-animal origin from third countries may be subject to enhanced official controls under Regulation (EU) 2021/608, with an updated reference date of 23 February 2026 in the Commission's information. For modern plant extracts, this means that, beyond the intrinsic conformity of the product, its geographical origin and import chain may also trigger increased scrutiny.
This level of oversight is more than just an administrative formality. It directly impacts product availability, delivery times, inventory stability, and sometimes even buyer confidence. A brand that knows its supply chains, secures its documentation, and works with tested batches is better equipped to offer a seamless experience. Conversely, companies that are vague about origin or certifications risk encountering obstacles that often ultimately penalize the end customer.
What this changes for brands and consumers
For businesses, the European message is becoming increasingly clear: botanical innovation remains possible, but it must be structured. Companies must know how to legally classify an extract, verify whether or not it falls under the novel food regulations, anticipate labeling requirements, avoid prohibited health claims, and organize imports that comply with customs and phytosanitary controls. This is no longer a market where a product sheet can be improvised around a trendy ingredient.
For consumers, this increased demand can, on the contrary, become a true indicator of quality. A well-presented product, lab-tested, clearly dosed, and sold within a coherent legal framework deserves more trust than one with vague promises or an ill-defined origin. In the world of CBD, flowers, resins, oils, or emerging cannabinoids, this logic is particularly important, as the market often mixes solid innovation with pure opportunism.
Ultimately, European regulations are slowly pushing the sector towards greater maturity. The best players aren't necessarily those who shout the loudest, but those who combine fair prices, speed, transparent documentation, and a careful understanding of the rules. For the adult buyer in France or Europe, this helps them make an informed distinction between product curiosity and genuine compliance.
Europe is therefore not closing the door to plant extracts modern ; it is simply imposing higher standards. Between novel food authorizations, scientific vigilance, restrictions on claims, and stricter border controls, the market is becoming more selective. This evolution may seem restrictive, but it also creates a healthier environment for reputable products.
In the coming years, the commercial success of plant extracts will increasingly depend on proof: proof of safety, proof of traceability, proof of compliance, and proof of analytical quality. This is excellent news for both consumers and responsible retailers. In a sector where innovation moves quickly, lasting trust remains the best competitive advantage.
